click enter text
full postview quarter okay split
caus chao emb cut futur estim
report financi result monday morn surpris
schedul tuesday cours accompani even
surpris news would split upjohn busi merg
w/ new distribut sharehold
result okay natur domin investor
attent decis split difficult model
recent restructur innov product establish product
divis latter renam upjohn yet provid restat
estim rejigg time put consum
divis jv gsk close soon ad
transact mix make much complex
gave first-tim partial guidanc parent ex-upjohn compani
remain behind also similarli gave partial guidanc upjohn
stand-alon financi net togeth seem repres shortfal
across divis vs like consensu model
news
sum part sotp basi residu seem worth
around includ cash get
newco investor ownership stake
newco sum around sotp methodolog see analysi
monday webcast slide
problem get rid upjohn close slightli monday
tuesday saw much bigger declin support sotp calcul
bodi report full analysi
inform stock cover see global
 juli issu monthli controversi report
trade fundament data
upsid target
factset/wolf research price juli
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
monday open
report result consensu revenu beat ep result origin
schedul tuesday
confirm press report weekend claim would combin upjohn divis
form new compani sharehold compani held joint confer
call discuss propos
saw share price declin follow anoth declin tuesday
overal impress result okay natur domin investor attent
decis split upjohn combin difficult model
recent restructur innov product renam biopharma establish product divis
renam upjohn yet provid restat estim substanti rejigg
time put consum health divis jv gsk transact close soon ad
upjohn split mix make even complex
pure perspect investor like understand strateg merit move
manag jettison declining-growth busi accomplish first set earli
split compani along line good bank bad bank howev split creat sum-
of-th part sotp problem price-to-earnings multipl market like ascrib upjohn
similar current spec pharma multipl often singl digit rang myl last week
averag pharma multipl pretti much everi pharma spin-out recent memori unit
divest higher valuat parent compani made independ lli elanco novn
alcon two recent exampl valu unlock sharehold often push howev
pfe case opposit larg reason compani abandon split first time
around full deliber chang sinc difficult know
price-to-earnings multipl busi like upjohn even lower ago
compound sotp problem also gave first-tim select element guidanc
ex-upjohn upjohn stand-alon even though wont ever stand alon transfer
directli guidanc assess impli set estim
forecast combin model beyond entir clear
potenti sourc varianc come certain element call headwind prevnar
like slow degre follow recent acip meet lipitor presum product
upjohn face tougher time china assum expand
see slide emerg market momentum china ruin
parti could also simpli dis-synergi split would seem natur reflect
revers usual synergi gain busi first combin although past
said split would creat materi dis-synergi
monday held webcast colleagu akash tewari cover discuss view
part show sotp analysi suggest fair valu mid-to-upp rang see
slide problem get rid upjohn webcast replay see
 newco live webcast monday share close presum
page
market work digest news end tuesday howev share close anoth
support sotp calcul
posit side manag deserv credit attempt re-shap busi variou way
exampl includ consum health jv gsk acquisit new opportun
come array spin upjohn growth residu compani better new revenu
stream pipelin futur bolt-on bigger impact posit
howev break hard instanc seem destroy valu near-term creat
assess pure sotp perspect long-term howev compani probabl better
addit detail us/eu drug compani cover see juli
issu monthli controversi report
term sale ep exhibit
revenu report sale vs consensu
ep report non-gaap ep vs consensu
ibranc sale vs consensu assuag concern us declin
drove increas util class
prevnar sale vs consensu
lyrica sale vs consensu
revenu combin revis vs prior mostli reflect
fact consum health busi soon fulli divest put jv gsk
ep combin revis vs prior attribut consum
divestitur attribut recent arry/therachon busi develop deal
ex-upjohn guid revenu closer also gave
approxim ratio sg percentag sale oper margin guidanc
upjohn stand-alon new owner upjohn guid upjohn revenu
ebidta provid ebidta figur ebit
ebit upjohn
page
revenu decreas ep decreas
move forecast reflect ex-upjohn even though upjohn still report
part next sever quarter ep estim
combin apples-to-orang comparison
price target lower pt base sum-of-the-part sotp analysi
residu worth price-to-earnings multipl new ep estim ex-upjohn
inclus impact interest expens receiv cash repres price-to-earnings multipl
expans use previous combin compani plu valu ownership
newco estim
confer call highlight pfe call came joint pfe myl call
follow split expect remainco revenu compound-annual-growth-rate higher otherwis would
upjohn china growth low mid singl digit percent
new ep guidanc includ impact chc jv format lag time
recogn minor interest payment well dilut impact arri therachon
oncolog stronger expect start year slight delay lyrica gener entri also help fx
wors howev goe impact impact revenu addit ep prevnar
acip chang xeljanz label chang also headwind
 ep suggest right provid specif ep guidanc
 upjohn spin mean pfe view rest busi view
noth chang versu prior view separ part busi bd distract
upjohn realli separ busi
 initi call plan split cite depress spec pharma multipl
would like comp eh busi impetu separ multipl
arguabl depress deal origin financi engin take advantag
multipl time deal driven oper valu creation given complementari profil
upjohn
 corpor em footprint impact deni neg still major
footprint em biopharma futur growth high still account revenu
grow tripl rate rest biopharma busi
page
 drove long-term revenu compound-annual-growth-rate upgrad mid-sd mid-to-high sd note
upjohn deal lyrica loe leav pfe revenu line posit impact also note smaller
base make easier grow
 deploy balanc sheet post upjohn spin continu say noth chang
continu activ bd preferenc smaller bolt-on larg scale never say never
excit pipelin moment regard intent pay debt
 talk achiev higher margin innov pharma dynam
remind ibt incom tax margin mid revenu grow abl get
leverag margin expans
 open use payment receiv upjohn/myl large-scal deal
close deal chang way view busi develop go forward
preferenti pursu early-to-l stage bolt-on acquisit regard cash payment current
earmark debt paydown
 top line growth assumpt mid high sd emb gener describ
risk-adjust pipelin go specif emb
govern purchas pattern advers impact prevnar pediatr revenu
quarter see demand impact acip recommend chang
expect proof concept data vaccin infant come month
still saw us growth driven promot ibranc doctor broadli util cdk
 time adjuv data two trial report may chang doubl
patient elig
priorit dose pursu higher dose regulatori submiss late earli
expect jv format gsk close aug one quarter lag term record
page
 updat launch come month cant speak time launch remain
excit opportun
 dmd safeti issu due believ total data set warrant continu develop
move pivot next year
impact china expect
 earli launch dynam patient alreadi diagnos beyond eap trial
receiv medicin bucket also get prescript fairli soon
see prior author process improv reject payer believ vast
major wildtyp patient
 drive increas size patient pool describ see good use
scintigraphi diagnosi tool patient come gener cardiologist well center excel
 eap clinic trial patient ever becom revenue-gener timelin
get diagnos patient therapi stream work patient eap
revenue-gener patient eap transfer commerci pay note there
process transit patient trial site commerci pay occur next sever
 break util pure cardiomyopathi mix phenotyp dont definit
number yet would assum similar wild-type/hereditari split
expect data
expect deal close near-term flag three key growth avenu colorect opportun
mek/braf royalti stream array research platform
 think anchor adjuv opportun base beacon data
seen opportun extend potenti data anchor polari pharo tissu agnost
page
continu work toward cap part senior pocket cost incentiv value-bas
reimburs establish robust biosimilar market
 view propos hc reform measur say support sfc bill entireti
provis support limit oop spend improv incent biosimilar
 price reduct done spread product say expect
eventu broaden includ product geographi
 revenu run rate china ex-upjohn around ibranc xeljanz
oper growth us driven rcc use combin bavencio keytruda
 co view loe window us main com goe may abl extend
determin
 upjohn opioid liabil say
may see impact recent label chang
 uc opportun second line use today educ effort help
expect addit atop dermat data jade trial end
page
exhibit show compani report actual result vs estim consensu
exhibit pfizer result vs wr estim consensu
page
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom outstand total profit profit incom
page
product revenu immunolog total
exhibit wr balanc sheet cash flow statement includ impact upjohn
page
flow statement earn in-process sale impair restructur defer compens asset flow oper activ sale sale busi net invest flow invest activ chang short term repay long-term common dividend flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock cent par valu paid-in comprehens treasuri stock sharehold liabil sharehold
